Michael  Feld net worth and biography

Michael Feld Biography and Net Worth

Executive Vice President and President, Life Sciences of Becton, Dickinson and Company

Michael Feld serves as the executive vice president and president of the Life Sciences segment for BD and serves as a member of the Executive Leadership Team.

As president of the BD Life Sciences segment, which includes Biosciences, Diagnostics Solutions and Specimen Management, Feld is responsible for an organization that is delivering advancements from discovery to diagnosis. Under his leadership, the BD Life Sciences segment is focused on delivering innovative diagnostics, research solutions and cutting-edge technologies that advance lab productivity and outcomes, enable the shift to new care settings and provide breakthrough insights and diagnostic data to advance care of many of the world’s most burdensome diseases such as cancer, immunologic disorders and infections.

Feld joined BD in 2024 from Veralto, a spin-off of Danaher, where he was president of Hach, a global leader in water quality products. Prior to that, Feld held several senior roles at Danaher, including senior vice president and general manager of Cepheid Europe, and served as president of other Danaher businesses, all focused on strategic planning, superior quality, associate development and cultural progression.

Feld earned his Bachelor of Science degree from Tulane University and his Master of Business Administration from Northwestern University’s Kellogg School of Management.

What is Michael Feld's net worth?

The estimated net worth of Michael Feld is at least $3.19 million as of December 1st, 2025. Mr. Feld owns 16,580 shares of Becton, Dickinson and Company stock worth more than $3,194,717 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Feld may own. Learn More about Michael Feld's net worth.

How do I contact Michael Feld?

The corporate mailing address for Mr. Feld and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on Michael Feld's contact information.

Has Michael Feld been buying or selling shares of Becton, Dickinson and Company?

During the last ninety days, Michael Feld has sold $25,104.57 of Becton, Dickinson and Company stock. Most recently, Michael Feld sold 75 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $193.36, for a transaction totalling $14,502.00. Following the completion of the sale, the executive vice president now directly owns 16,580 shares of the company's stock, valued at $3,205,908.80. Learn More on Michael Feld's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Richard Byrd (EVP and President, Interventional Segment ), Richard Byrd (EVP), Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Michael Feld (Executive Vice President and President, Life Sciences), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), Jeffrey Henderson (Director), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Shana Neal (EVP and Chief People Officer), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), Bertram Scott (Director), David Shan (EVP), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, Becton, Dickinson and Company insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $350,430.00. During the last year, insiders at the medical instruments supplier sold shares 18 times. They sold a total of 17,960 shares worth more than $3,831,767.26. The most recent insider tranaction occured on December, 1st when EVP Michael Feld sold 75 shares worth more than $14,502.00. Insiders at Becton, Dickinson and Company own 0.4% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 12/1/2025.

Michael Feld Insider Trading History at Becton, Dickinson and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2025Sell75$193.36$14,502.0016,580View SEC Filing Icon  
10/27/2025Sell57$186.01$10,602.578,245View SEC Filing Icon  
9/26/2025Sell58$181.03$10,499.748,302View SEC Filing Icon  
See Full Table

Michael Feld Buying and Selling Activity at Becton, Dickinson and Company

This chart shows Michael Feld's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $193.68
Low: $192.09
High: $194.10

50 Day Range

MA: $188.09
Low: $176.22
High: $195.48

2 Week Range

Now: $193.68
Low: $162.29
High: $251.99

Volume

1,253,147 shs

Average Volume

2,412,403 shs

Market Capitalization

$55.28 billion

P/E Ratio

33.22

Dividend Yield

2.15%

Beta

0.25